Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Merck KGaA : Effect Pigments for Architecture: Merck Exhibits at the Middle East Coatings Show 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2012 | 10:24am CEST

Darmstadt/Germany, March 5, 2012 - Merck will be presenting its effect pigments for architecture at the Middle East Coatings Show in Dubai from March 12 to 14, 2012. This exhibition is the most important platform for the coatings sector in the Middle East and the Gulf region. The focus of the exhibition will be on architectural applications, which have been seeing rapid growth in the region for the past several years. The trend toward gold and silver shades, which can currently be seen in lifestyle products and interior designs, is also being reflected in architecture.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
06/21MERCK KGAA : Darmstadt, Germany Drives Thought Leadership in Ethical Gene Editin..
AQ
06/20MERCK : Darmstadt, Germany, Announces Collaborations and Investment in all Three..
PU
06/20MERCK : Darmstadt, Germany Opens OLED Technology Center China in Shanghai
PU
06/20Merck KGaA Partners With Alibaba Health in China
DJ
06/19MERCK : to Distribute HistoCyte Laboratories Products
DJ
06/19MERCK : MilliporeSigma Signs Exclusive Agreement with HistoCyte Laboratories to ..
PU
06/18MERCK : Data Presented at EAN 2018 Provide Further Insight into the Efficacy of ..
PU
06/16MERCK : Survey Reveals Most Thyroid Disorder Patients Find Road to Diagnosis Lon..
AQ
06/14MERCK : New Findings from Merck KGaA in the Area of Non-Small Cell Lung Cancer R..
AQ
06/14STUDIES FROM MERCK KGAA PROVIDE NEW : Real-world evidence for...
AQ
More news
News from SeekingAlpha
06/13YOUR DAILY PHARMA SCOOP : Tetraphase Positive Data, MediWound In Phase 3, Allerg.. 
06/133 THINGS IN BIOTECH, JUNE 12 : MET Targeting Gets On Your Radar 
06/11Merck KGaA's tepotinib successful two mid-stage liver cancer studies 
06/07MINING ASCO 2018'S GOLD, PART 13 : Breathe Deep, This Is The Final Chapter 
05/23MERCK KG&A (MKGAY) Presents At 2018 UBS Global Healthcare Conference - Slides.. 
Financials (€)
Sales 2018 14 889 M
EBIT 2018 2 897 M
Net income 2018 2 174 M
Debt 2018 7 414 M
Yield 2018 1,53%
P/E ratio 2018 15,65
P/E ratio 2019 17,44
EV / Sales 2018 1,22x
EV / Sales 2019 1,05x
Capitalization 10 694 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 96,6 €
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-7.81%12 435
ABBVIE1.59%155 911
KYOWA HAKKO KIRIN CO LTD3.65%12 070
JAZZ PHARMACEUTICALS PLC36.04%11 043
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD71.34%10 038
CONVATEC GROUP6.62%5 622